Analysts Offer Predictions for Cosmos Health FY2025 Earnings

Cosmos Health Inc. (NASDAQ:COSM) – Research analysts at Zacks Small Cap issued their FY2025 EPS estimates for shares of Cosmos Health in a report issued on Tuesday, January 13th. Zacks Small Cap analyst B. Sorensen expects that the company will post earnings per share of ($0.25) for the year. The consensus estimate for Cosmos Health’s current full-year earnings is ($0.78) per share. Zacks Small Cap also issued estimates for Cosmos Health’s Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.02 EPS, FY2026 earnings at ($0.11) EPS, Q1 2027 earnings at $0.00 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.03 EPS, Q4 2027 earnings at $0.03 EPS and FY2027 earnings at $0.07 EPS.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.16). The firm had revenue of $17.11 million during the quarter, compared to analysts’ expectations of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%.

A number of other brokerages have also recently commented on COSM. Wall Street Zen raised shares of Cosmos Health to a “hold” rating in a research note on Saturday, September 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Cosmos Health Trading Down 3.2%

Shares of COSM stock opened at $0.52 on Thursday. Cosmos Health has a fifty-two week low of $0.28 and a fifty-two week high of $1.32. The stock has a market cap of $19.63 million, a P/E ratio of -0.70 and a beta of 5.37. The business has a fifty day simple moving average of $0.55 and a 200-day simple moving average of $0.73. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.

Insider Transactions at Cosmos Health

In other news, CEO Grigorios Siokas acquired 493,495 shares of Cosmos Health stock in a transaction that occurred on Wednesday, January 14th. The shares were purchased at an average cost of $0.45 per share, for a total transaction of $222,072.75. Following the completion of the purchase, the chief executive officer directly owned 7,738,474 shares of the company’s stock, valued at $3,482,313.30. This trade represents a 6.81% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders purchased a total of 1,579,590 shares of company stock worth $805,169 in the last 90 days. Corporate insiders own 25.10% of the company’s stock.

Hedge Funds Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC lifted its position in Cosmos Health Inc. (NASDAQ:COSM) by 133.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,507 shares of the company’s stock after buying an additional 128,776 shares during the period. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.61% of the company’s stock.

Key Cosmos Health News

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Significant CEO insider accumulation — CEO Grigorios Siokas disclosed a purchase of 493,495 shares at ~$0.45 on Jan. 14 (raising his stake ~6.8%), adding to multiple buys earlier in January; heavy insider buying signals management confidence and likely underpins short‑term buying interest. Read More.
• Positive Sentiment: Zacks Small‑Cap initiation with optimistic projections — Zacks initiated coverage and models revenue growth (~$130M+ by 2027) and a path to positive EPS by FY2027, which is a near‑term sentiment booster for a micro‑cap stock. Read More.
• Positive Sentiment: Growing institutional interest — filings show funds (e.g., Citadel) increased positions recently, which can improve liquidity and provide steady demand for shares. Read More.
• Neutral Sentiment: Zacks’ forward EPS trajectory is model‑driven — the research projects FY2027 EPS ~ $0.07, but these estimates depend on execution (U.S. expansion, AI R&D, product rollouts) and are not confirmed results. Read More.
• Negative Sentiment: Recent fundamentals remain weak — the company missed on EPS in its last report, posts negative margins and ROE, and consensus still forecasts a full‑year loss (~‑$0.78), keeping near‑term earnings risk elevated. Read More.
• Negative Sentiment: Valuation and disclosure caveats — Zacks used a high discount rate in its model and the report was paid/sponsored, which raises impartiality and model‑assumption risk for investors. Read More.
• Negative Sentiment: High volatility and small‑cap risk — COSM’s tiny market cap and high beta make the share price prone to sharp swings; broker coverage is limited and consensus ratings skew toward Sell, increasing trading risk. Read More.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.